Actuate Therapeutics, INC

Actuate Therapeutics received a notice from Nasdaq regarding its Market Value of Listed Securities (MVLS) falling below the required $50 million threshold, with 180 days to regain compliance.

Actuate Therapeutics stockholders elected two Class II directors and ratified the appointment of Crowe LLP as auditor.

Actuate Therapeutics received FDA clearance for a Phase 1/2 study of its oral elraglusib tablet, aiming to improve patient outcomes in multiple solid tumor indications.

Actuate Therapeutics adds Dr. Martin Huber, an experienced oncology drug developer, to its Board of Directors to bolster its leadership in advancing novel cancer therapies.

Actuate Therapeutics announced positive follow-up data from its Phase 2 trial of elraglusib, showing extended overall survival benefit in metastatic pancreatic cancer patients.

Actuate Therapeutics, Inc. has entered into an At-the-Market sales agreement to potentially raise up to $100 million through the sale of common stock.

Actuate Therapeutics reported a net loss of $5.6 million for Q1 2026, with a decrease in R&D spending and ongoing concerns about its ability to continue as a going concern beyond July 2026.

Actuate Therapeutics reported its Q3 2025 results, showcasing positive topline data from its Phase 2 mPDAC trial for elraglusib and detailing recent capital raises to fund ongoing operations.

Actuate Therapeutics reported promising Phase 2 results for elraglusib in pancreatic cancer but faces substantial doubt about its ability to continue as a going concern beyond October 2025.

Actuate Therapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Actuate Therapeutics reports its third quarter 2024 financial results, highlighting its transition to a public company following a successful IPO and continued clinical development of elraglusib.

Actuate Therapeutics, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results, highlighting ongoing clinical trials and recent corporate developments including its IPO.

Actuate Therapeutics' lead drug candidate, elraglusib, demonstrated a statistically significant improvement in median overall survival for metastatic pancreatic cancer in a Phase 2 trial.

Actuate Therapeutics' 10-K filing highlights positive interim Phase 2 results for elraglusib in mPDAC and outlines plans for future clinical trials and development.

Director Todd Thomson was granted 15,000 stock options in Actuate Therapeutics, Inc. with an exercise price of $2.42.

Director Roger Sawhney was granted 15,000 stock options in Actuate Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director Amy L. Ronneberg was granted 15,000 stock options in Actuate Therapeutics, Inc. as disclosed in a recent SEC Form 4 filing.

Director Jason A. Keyes was granted 15,000 stock options in Actuate Therapeutics, Inc. as part of a standard equity incentive.

Director Martin H. Huber Jr. was granted 15,000 stock options in Actuate Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director Aaron G.L. Fletcher was granted 15,000 stock options in Actuate Therapeutics, Inc. as part of a standard equity compensation arrangement.

Actuate Therapeutics, Inc. has scheduled its 2026 Annual Meeting of Stockholders for May 21, 2026, to vote on director elections and auditor ratification.

Actuate Therapeutics, Inc. has filed a definitive proxy statement with the SEC.

Actuate Therapeutics announces its 2025 annual meeting of stockholders to be held virtually on May 22, 2025, to vote on director elections and the ratification of the independent accounting firm.

Actuate Therapeutics, a clinical-stage biopharmaceutical company, filed an S-1 registration statement for the resale of 1.33 million common shares by existing stockholders, highlighting significant financial challenges including a going concern warning.

Actuate Therapeutics intends to offer up to 3,904,374 shares of common stock through a committed equity facility with B. Riley Principal Capital II, potentially raising up to $50 million for working capital and general corporate purposes.

Actuate Therapeutics files for an IPO to raise $29.5 million, aiming to advance its cancer therapies and list on the Nasdaq Capital Market.

Actuate Therapeutics updates its S-1 filing, detailing the initial public offering of 2,777,778 shares of common stock with an estimated price range of $8.00 to $10.00 per share.

Actuate Therapeutics updates its S-1 filing, highlighting clinical trial advancements and plans for its lead drug, elraglusib, in treating metastatic pancreatic cancer and other malignancies.

Actuate Therapeutics advances its IPO plans with an updated filing, focusing on developing cancer therapies through GSK-3 inhibition.

Actuate Therapeutics, Inc. has completed a private placement, raising nearly $500,000 through the sale of common stock and warrants to Bios 2024 Co-Invest, LP.

An amendment to a Schedule 13D filing reveals that the Bios Equity Partners group, including key individuals Leslie W. Kreis and Aaron G.L. Fletcher, has updated its beneficial ownership in Actuate Therapeutics, Inc., with the group's aggregate stake now exceeding 50% of the common stock.

Voss Capital and affiliated entities have filed an amended Schedule 13G, reporting beneficial ownership of 7.7% of Actuate Therapeutics, Inc. common stock as of March 31, 2026.

Voss Capital, LP and affiliated entities have reported a 5.3% beneficial ownership stake in Actuate Therapeutics, Inc. common stock.